nach oben

Diabetologia

Erschienen in:

01.11.2014 | Meta-analysis

Prediabetes and the risk of cancer: a meta-analysis

verfasst von: Yi Huang, Xiaoyan Cai, Miaozhen Qiu, Peisong Chen, Hongfeng Tang, Yunzhao Hu, Yuli Huang

Erschienen in: Diabetologia | Ausgabe 11/2014

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

The results from prospective cohort studies of prediabetes (impaired fasting glucose and/or impaired glucose tolerance) and risk of cancer are controversial. We conducted a meta-analysis to evaluate the risk of cancer in association with impaired fasting glucose and impaired glucose tolerance.

Methods

The PubMed, EMBASE and Cochrane Library databases were searched for prospective cohort studies with data on prediabetes and cancer. Two independent reviewers assessed the reports and extracted the data. Prospective studies were included if they reported adjusted RRs with 95% CIs for the association between cancer and prediabetes. Subgroup analyses were conducted according to endpoint, age, sex, ethnicity, duration of follow-up and study characteristics.

Results

Data from 891,426 participants were derived from 16 prospective cohort studies. Prediabetes was associated with an increased risk of cancer overall (RR 1.15; 95% CI 1.06, 1.23). The results were consistent across cancer endpoint, age, duration of follow-up and ethnicity. There was no significant difference for the risk of cancer with different definitions of prediabetes. In a site-specific cancer analysis, prediabetes was significantly associated with increased risks of cancer of the stomach/colorectum, liver, pancreas, breast and endometrium (all p < 0.05), but not associated with cancer of the bronchus/lung, prostate, ovary, kidney or bladder. The risks of site-specific cancer were significantly different (p = 0.01) and were highest for liver, endometrial and stomach/colorectal cancer.

Conclusions/interpretation

Overall, prediabetes was associated with an increased risk of cancer, especially liver, endometrial and stomach/colorectal cancer.

Nur mit Berechtigung zugänglich

DeFronzo RA, Abdul-Ghani M (2011) Assessment and treatment of cardiovascular risk in prediabetes: impaired glucose tolerance and impaired fasting glucose. Am J Cardiol 108:3B–24BPubMedCrossRef

Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (2003) Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 26(Suppl 1):S5–S20

World Health Organization (WHO) Consultation (2006) Definition and diagnosis of diabetes and intermediate hyperglycaemia. www.who.int/diabetes/publications/Definition%20and%20diagnosis%20of%20diabetes_new.pdf. Accessed 1 Jan 2014

Ryden L, Grant PJ, Anker SD et al (2013) ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 34:3035–3087PubMedCrossRef

Forouhi NG, Balkau B, Borch-Johnsen K et al (2006) The threshold for diagnosing impaired fasting glucose: a position statement by the European Diabetes Epidemiology Group. Diabetologia 49:822–827PubMedCrossRef

Buysschaert M, Sadikot S (2013) Diabetes and cancer: a 2013 synopsis. Diabetes Metab Syndr 7:247–250PubMedCrossRef

Seshasai SR, Kaptoge S, Thompson A et al (2011) Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 364:829–841PubMedCrossRef

Hirakawa Y, Ninomiya T, Mukai N et al (2012) Association between glucose tolerance level and cancer death in a general Japanese population: the Hisayama Study. Am J Epidemiol 176:856–864PubMedCrossRef

Lambe M, Wigertz A, Garmo H, Walldius G, Jungner I, Hammar N (2011) Impaired glucose metabolism and diabetes and the risk of breast, endometrial, and ovarian cancer. Cancer Causes Control 22:1163–1171PubMedCrossRef

10.

Parekh N, Lin Y, Vadiveloo M, Hayes RB, Lu-Yao GL (2013) Metabolic dysregulation of the insulin-glucose axis and risk of obesity-related cancers in the Framingham Heart Study-offspring cohort (1971–2008). Cancer Epidemiol Biomarkers Prev 22:1825–1836PubMedCrossRef

11.

Stattin P, Bjor O, Ferrari P et al (2007) Prospective study of hyperglycemia and cancer risk. Diabetes Care 30:561–567PubMedCrossRef

12.

Yun JE, Jo I, Park J et al (2006) Cigarette smoking, elevated fasting serum glucose, and risk of pancreatic cancer in Korean men. Int J Cancer 119:208–212PubMedCrossRef

13.

Zhou XH, Qiao Q, Zethelius B et al (2010) Diabetes, prediabetes and cancer mortality. Diabetologia 53:1867–1876PubMedCrossRef

14.

Chung H, Chen S, Li M (2009) Diabetes and risk of death from cancer of the prostate, kidney, and urinary bladder. Urology 74:S36–S37CrossRef

15.

Gwack J, Hwang SS, Ko KP et al (2007) Fasting serum glucose and subsequent liver cancer risk in a Korean prospective cohort. J Prev Med Public Health 40:23–28 [article in Korean]PubMedCrossRef

16.

Harding JL, Soderberg S, Shaw JE et al (2012) All-cause cancer mortality over 15 years in multi-ethnic Mauritius: the impact of diabetes and intermediate forms of glucose tolerance. Int J Cancer 131:2385–2393PubMedCrossRef

17.

Kowall B, Rathmann W, Heier M et al (2011) Categories of glucose tolerance and continuous glycemic measures and mortality. Eur J Epidemiol 26:637–645PubMedCrossRef

18.

Lu W, Resnick HE, Jain AK et al (2003) Effects of isolated post-challenge hyperglycemia on mortality in American Indians: the Strong Heart Study. Ann Epidemiol 13:182–188PubMedCrossRef

19.

Stroup DF, Berlin JA, Morton SC et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283:2008–2012PubMedCrossRef

20.

The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20:1183–1197

21.

Wells GA, Shea B, O’Connell D et al (2003) The Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 1 Jan 2014

22.

Lee M, Saver JL, Chang KH, Liao HW, Chang SC, Ovbiagele B (2010) Low glomerular filtration rate and risk of stroke: meta-analysis. BMJ 341:c4249PubMedCrossRefPubMedCentral

23.

Imdad A, Yakoob MY, Bhutta ZA (2011) The effect of folic acid, protein energy and multiple micronutrient supplements in pregnancy on stillbirths. BMC Public Health 11(Suppl 3):S4PubMedCrossRefPubMedCentral

24.

Stengard JH, Tuomilehto J, Pekkanen J et al (1992) Diabetes mellitus, impaired glucose tolerance and mortality among elderly men: the Finnish cohorts of the Seven Countries Study. Diabetologia 35:760–765PubMed

25.

Balkau B, Forhan A, Eschwege E (2002) Two hour plasma glucose is not unequivocally predictive for early death in men with impaired fasting glucose: more results from the Paris Prospective Study. Diabetologia 45:1224–1230PubMedCrossRef

26.

Mink PJ, Shahar E, Rosamond WD, Alberg AJ, Folsom AR (2002) Serum insulin and glucose levels and breast cancer incidence: the atherosclerosis risk in communities study. Am J Epidemiol 156:349–352PubMedCrossRef

27.

Saydah SH, Loria CM, Eberhardt MS, Brancati FL (2003) Abnormal glucose tolerance and the risk of cancer death in the United States. Am J Epidemiol 157:1092–1100PubMedCrossRef

28.

Perseghin G, Calori G, Lattuada G et al (2012) Insulin resistance/hyperinsulinemia and cancer mortality: the Cremona study at the 15th year of follow-up. Acta Diabetol 49:421–428PubMedCrossRef

29.

Shaw J (2011) Diagnosis of prediabetes. Med Clin N Am 95:341–352PubMedCrossRef

30.

De Caterina R, Madonna R (2010) Impaired fasting plasma glucose and long-term cardiovascular risk: still a foggy relationship. Eur Heart J 31:1159–1162PubMedCrossRef

31.

Abe R, Yamagishi S (2008) AGE-RAGE system and carcinogenesis. Curr Pharm Des 14:940–945PubMedCrossRef

32.

Rehman A, Nourooz-Zadeh J, Moller W, Tritschler H, Pereira P, Halliwell B (1999) Increased oxidative damage to all DNA bases in patients with type II diabetes mellitus. FEBS Lett 448:120–122PubMedCrossRef

33.

Tabak O, Gelisgen R, Erman H et al (2011) Oxidative lipid, protein, and DNA damage as oxidative stress markers in vascular complications of diabetes mellitus. Clin Invest Med 34:E163–E171PubMed

34.

Pereira CS, Molz P, Palazzo RP et al (2013) DNA damage and cytotoxicity in adult subjects with prediabetes. Mutat Res 753:76–81PubMedCrossRef

35.

Faerch K, Borch-Johnsen K, Holst JJ, Vaag A (2009) Pathophysiology and aetiology of impaired fasting glycaemia and impaired glucose tolerance: does it matter for prevention and treatment of type 2 diabetes? Diabetologia 52:1714–1723PubMedCrossRef

36.

Gao S, Li A, Liu F et al (2013) NCOA5 haploinsufficiency results in glucose intolerance and subsequent hepatocellular carcinoma. Cancer Cell 24:725–737PubMedCrossRef

37.

Zhang F, Yang Y, Skrip L et al (2012) Diabetes mellitus and risk of prostate cancer: an updated meta-analysis based on 12 case–control and 25 cohort studies. Acta Diabetol 49(Suppl 1):S235–S246

38.

Frayling TM, Colhoun H, Florez JC (2008) A genetic link between type 2 diabetes and prostate cancer. Diabetologia 51:1757–1760PubMedCrossRef

39.

Bullard KM, Saydah SH, Imperatore G et al (2013) Secular changes in U.S. prediabetes prevalence defined by hemoglobin A1c and fasting plasma glucose: National Health and Nutrition Examination Surveys, 1999–2010. Diabetes Care 36:2286–2293PubMedCrossRefPubMedCentral

40.

Nathan DM, Davidson MB, DeFronzo RA et al (2007) Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 30:753–759PubMedCrossRef

41.

Leone A, Di Gennaro E, Bruzzese F, Avallone A, Budillon A (2014) New perspective for an old antidiabetic drug: metformin as anticancer agent. Cancer Treat Res 159:355–376PubMedCrossRef

42.

American Diabetes Association (2013) Diagnosis and classification of diabetes mellitus. Diabetes Care 36(Suppl 1):S67–S74CrossRefPubMedCentral

Titel: Prediabetes and the risk of cancer: a meta-analysis
verfasst von: Yi Huang
Xiaoyan Cai
Miaozhen Qiu
Peisong Chen
Hongfeng Tang
Yunzhao Hu
Yuli Huang
Publikationsdatum: 01.11.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: Diabetologia / Ausgabe 11/2014
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-014-3361-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Aims/hypothesis

Methods

Results

Conclusions/interpretation

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2014

Global DNA methylation levels in human adipose tissue are related to fat distribution and glucose homeostasis

von Hippel–Lindau gene disruption in mouse pancreatic progenitors and its consequences on endocrine differentiation in vivo: importance of HIF1-α and VEGF-A upregulation

Timing and intensity of exercise for glucose control

Variants associated with type 2 diabetes identified by the transethnic meta-analysis study: assessment in American Indians and evidence for a new signal in LPP

Does genetic heterogeneity account for the divergent risk of type 2 diabetes in South Asian and white European populations?

Favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study